Zelira Therapeutics Limited
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment o… Read more
Zelira Therapeutics Limited (ZLDAF) - Total Liabilities
Latest total liabilities as of June 2025: $5.59 Million USD
Based on the latest financial reports, Zelira Therapeutics Limited (ZLDAF) has total liabilities worth $5.59 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zelira Therapeutics Limited - Total Liabilities Trend (2015–2025)
This chart illustrates how Zelira Therapeutics Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zelira Therapeutics Limited Competitors by Total Liabilities
The table below lists competitors of Zelira Therapeutics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yaprak Sut ve Besi Ciftlikleri Sanayi ve Ticaret AS
IS:YAPRK
|
Turkey | TL220.27 Million |
|
Hammer Fiber Optics Holdings Corp
PINK:HMMR
|
USA | $1.04 Million |
|
Longhorn Exploration Corp
V:LEX
|
Canada | CA$2.03K |
|
Rich Goldman Holdings Limited
F:MRU3
|
Germany | €263.92 Million |
|
Painreform Ltd
NASDAQ:PRFX
|
USA | $2.72 Million |
|
TinOne Resources Inc.
OTCQB:TORCF
|
USA | $1.47 Million |
|
23B
F:23B
|
Germany | €2.43 Million |
|
Interactive Strength Inc. Common Stock
NASDAQ:TRNR
|
USA | $67.98 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Zelira Therapeutics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zelira Therapeutics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zelira Therapeutics Limited (2015–2025)
The table below shows the annual total liabilities of Zelira Therapeutics Limited from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $5.59 Million | -40.25% |
| 2024-06-30 | $9.36 Million | +329.42% |
| 2023-06-30 | $2.18 Million | +8.35% |
| 2022-06-30 | $2.01 Million | +30.92% |
| 2021-06-30 | $1.54 Million | +23.71% |
| 2020-06-30 | $1.24 Million | +204.91% |
| 2019-06-30 | $407.24K | +309.60% |
| 2018-06-30 | $99.42K | +40.78% |
| 2017-06-30 | $70.62K | -75.68% |
| 2016-06-30 | $290.42K | +649.79% |
| 2015-06-30 | $38.73K | -- |